HSIC vs SPRY · P/E 24, rev $12.67B vs rev $89.1M
Henry Schein Inc (HSIC) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the HSIC and SPRY stock pages for the full models.
Not investment advice.